These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 17575373)

  • 1. Analysis of factors causing hyperkalemia.
    Takaichi K; Takemoto F; Ubara Y; Mori Y
    Intern Med; 2007; 46(12):823-9. PubMed ID: 17575373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
    Ahmed A
    J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Renin-Angiotensin Aldosterone System Inhibition on Serum Potassium Levels among Peritoneal Dialysis Patients.
    Ribeiro SC; Figueiredo AE; Barretti P; Pecoits-Filho R; de Moraes TP;
    Am J Nephrol; 2017; 46(2):150-155. PubMed ID: 28738355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?
    Bakris GL; Weir MR
    Arch Intern Med; 2000 Mar; 160(5):685-93. PubMed ID: 10724055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
    Bandak G; Sang Y; Gasparini A; Chang AR; Ballew SH; Evans M; Arnlov J; Lund LH; Inker LA; Coresh J; Carrero JJ; Grams ME
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW; Won YW; Yi JH; Kim HJ
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community setting.
    Kurnik D; Vesterman-Landes J; Bialik M; Katzir I; Lomnicky Y; Halkin H; Loebstein R
    Clin Ther; 2011 Apr; 33(4):456-64. PubMed ID: 21635991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adequate intake of potassium does not cause hyperkalemia in hypertensive individuals taking medications that antagonize the renin angiotensin aldosterone system.
    Malta D; Arcand J; Ravindran A; Floras V; Allard JP; Newton GE
    Am J Clin Nutr; 2016 Oct; 104(4):990-994. PubMed ID: 27581475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis.
    Maddirala S; Khan A; Vincent A; Lau K
    Am J Med Sci; 2008 Oct; 336(4):330-5. PubMed ID: 18854676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations.
    Parikh RV; Nash DM; Brimble KS; Markle-Reid M; Tan TC; McArthur E; Khoshniat-Rad F; Sood MM; Zheng S; Pravoverov L; Nesrallah GE; Garg AX; Go AS
    Circ Cardiovasc Qual Outcomes; 2020 Sep; 13(9):e006415. PubMed ID: 32873054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
    Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein A; Andrade SE; Lafata JE; Roblin D; Davis RL; Gunter MJ; Platt R
    Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):55-64. PubMed ID: 16470693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease.
    Garlo KG; Bates DW; Seger DL; Fiskio JM; Charytan DM
    JAMA Netw Open; 2018 Nov; 1(7):e183874. PubMed ID: 30646338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Renin-Angiotensin System Blockers Increases Serum Potassium in Anuric Hemodialysis Patients.
    Movilli E; Camerini C; Gaggia P; Zubani R; Cancarini G
    Am J Nephrol; 2018; 48(2):79-86. PubMed ID: 30071530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
    Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Raebel MA
    Cardiovasc Ther; 2012 Jun; 30(3):e156-66. PubMed ID: 21883995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease.
    Oktaviono YH; Kusumawardhani N
    Acta Med Indones; 2020 Jan; 52(1):74-79. PubMed ID: 32291375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
    Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S
    Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE-inhibitor or AT2-antagonist therapy of renal transplant recipients is associated with an increase in serum potassium concentrations.
    Mitterbauer C; Heinze G; Kainz A; Kramar R; Hörl WH; Oberbauer R
    Nephrol Dial Transplant; 2008 May; 23(5):1742-6. PubMed ID: 18234845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
    Hirai T; Yamaga R; Fujita A; Itoh T
    J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.